Wachtell, Lipton, Rosen & Katz and Clifford Chance served as Pfizer’s legal advisors, and Skadden, Arps, Slate, Meagher & Flom served as its tax advisor for...
You must be a Standard 1 Year member to access this content.
Ropes & Gray, working alongside Walkers, represented Pfizer, while Skadden advised Centerview Partners, the financial advisor to Biohaven Pharmaceutical on the deal. S&C, Maples and Calder...
You must be a Standard 1 Year member to access this content.
Goodwin advised ReViral on the deal. Clifford Chance advised Pfizer. ReViral announced its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Pfizer Inc. in the deal, while Cooley represented Arena Pharmaceuticals. Debevoise & Plimpton advised Evercore Group and Guggenheim Securities as financial advisors...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Pfizer in the deal. Pfizer announced its collaboration arrangement with Biohaven Pharmaceutical Company to commercialize rimegepant, a therapy approved in the U.S. as...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz represented Pfizer in the transaction. Pfizer Inc. (NYSE: PFE) has entered into an agreement with Altaris Capital Partners, LLC, a healthcare...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
